- Trial Phase
- Filed/Pre-NDA resubmission (already approved as Inpefa for heart failure)
- Time to Market
- Uncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.
- Why 6/10
- The next hard catalyst is Zynquista's NDA resubmission, expected in Q4 2026 (~1-3 months away). This is a major de-risking event for a drug that is a primary pipeline value driver, but Lexicon also has other programs (approved Inpefa, SONATA-HCM Phase 3, LX9851), so it is not a pure single-asset binary.
Watch for Zynquista NDA resubmission announcement in Q4 2026 — that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.
Price Chart
Executive Summary
Zynquista (sotagliflozin) is Lexicon Pharmaceuticals' type 1 diabetes drug candidate — a first-in-class dual SGLT1/SGLT2 inhibitor already approved as Inpefa for heart failure. The FDA rejected it for type 1 diabetes in December 2024, and Lexicon submitted additional data in September 2025 to address the CRL. The company now expects to resubmit the NDA in Q4 2026, representing the next major catalyst. The stock trades at ~$2.19 with a mean analyst target of $3.86, but the drug faces significant regulatory headwinds including two prior FDA rejections and an 11-3 advisory committee vote against it. Short interest is elevated, and institutional positioning is mixed heading into the resubmission.
How It Works
Zynquista (sotagliflozin) is a first-in-class dual SGLT1/SGLT2 inhibitor — an oral pill that lowers blood sugar through two pathways: it blocks glucose reabsorption in the kidneys (like other SGLT2 inhibitors) and also delays glucose absorption from food in the gut by inhibiting SGLT1. This dual mechanism is unique among diabetes drugs. Under the brand name Inpefa, the same molecule is already FDA-approved to reduce cardiovascular death and heart failure hospitalization.
Trial Status
Zynquista was studied in three Phase 3 trials (inTandem1-3) for type 1 diabetes with CKD. The FDA issued a Complete Response Letter (CRL) in December 2024, rejecting the NDA for this indication. Lexicon submitted additional clinical data from investigator-sponsored trials in September 2025 to address the CRL. After a Type D meeting with the FDA in Q4 2025, the company is targeting an NDA resubmission in Q4 2026.
The Two-Sided Case
Upcoming Catalysts
- Zynquista NDA resubmission to FDA expected Q4 2026 (next ~3 months)
- SONATA-HCM Phase 3 topline data expected Q1 2027 (separate pipeline asset)
- Potential Novo Nordisk milestone payment (~$10M) later in 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
LEXICON PHARMACEUTICALS, INC. 8-K LXRX ·Originating report